Polyrizon - רווח נקי למניה אחת בשנים עשר החודשים האחרונים PLRZ

Polyrizon Ltd is scaling the production of nasal barriers through partnerships with biomedical holdings. Patent protection for polymer sprays and stringent FDA requirements create significant barriers to entry for competitors. The TTM annual net income per share dynamics reflect market expectations, while 99.40 determines the latest valuation metric. Growth is driven by high margins on over-the-counter products and government biodefense contracts.

To assess the financial stability of Polyrizon Ltd (PLRZ), investors must track the real growth of earnings per share. This metric compares the current trailing 12-month net income with the same period last year, revealing the gap between paper reporting and actual cash flow. For a developer of nasal drug delivery systems, this trend reflects the commercialization efficiency of joint laboratory projects. By analyzing the YoY EPS dynamics over the last 12 months, one can determine the risk of asset overvaluation, allowing investors to avoid allocating capital to a company with artificially inflated indicators.